目的:检验世界卫生组织残疾人生存质量量表一般残疾版本(WHOQOL-DIS Scales for PD)中文版的可接受性、信度和效度,以便用于中国残疾人的生存质量的研究。方法:采用多阶段分层随机抽样的方法,从广州市抽取一般残疾人(除智力残疾的其他...目的:检验世界卫生组织残疾人生存质量量表一般残疾版本(WHOQOL-DIS Scales for PD)中文版的可接受性、信度和效度,以便用于中国残疾人的生存质量的研究。方法:采用多阶段分层随机抽样的方法,从广州市抽取一般残疾人(除智力残疾的其他残疾人)807名。间隔1周后,对自愿进行重复调查的109人进行重测。对量表进行可接受性、信度和效度检验,并以生活满意度量表(SWLS)为校标。结果:量表回收率为99.2%,除了性生活满意度条目缺失率为35.7%,其余条目的缺失率均小于5.0%。量表5个领域的Cronbachα系数为0.77~0.84;间隔1周后重测ICC为0.82~0.91。量表条目与所属领域得分的秩相关系数为0.30~0.84,高于与其他领域的相关性;验证性因子分析显示量表的拟合较好(χ2=2405.57,df=569,RM SEA=0.06,GFI=0.85,CFI=0.87);量表5个领域得分与SWLS得分呈正相关(r=0.15~0.45,均P<0.05)。结论:世界卫生组织残疾人生存质量量表一般残疾版本中文版具有较好的可接受性、信度和效度,可用于中国残疾人生存质量的研究。展开更多
Health related quality of life(HRQOL) is increasingly recognized as an important clinical parameter and research endpoint in patients with hepatocellular carcinoma(HCC). HRQOL in HCC patients is multifaceted and affec...Health related quality of life(HRQOL) is increasingly recognized as an important clinical parameter and research endpoint in patients with hepatocellular carcinoma(HCC). HRQOL in HCC patients is multifaceted and affected by medical factor which encompasses HCC and its complications, oncological and palliative treatment for HCC, underlying liver disease, as well as the psychological, social or spiritual reaction to the disease. Many patients presented late with advanced disease and limited survival, plagued with multiple symptoms, rendering QOL a very important aspect in their general well being. Various instruments have been developed and validated to measure and report HRQOL in HCC patients, these included general HRQOL instruments, e.g., Short form(SF)-36, SF-12, Euro Qo L-5D, World Health Organization Quality of Life Assessment 100(WHOQOL-100), World Health Organization Quality of Life Assessment abbreviated version; general cancer HRQOL instruments, e.g., the European Organisation for Research and Treatment of Cancer(EORTC) QLQ-C30, Functional Assessment of Cancer Therapy(FACT)-General, Spitzer Quality of Life Index; and liver-cancer specific HRQOL instruments, e.g., EORTC QLQ-HCC18, FACT-Hepatobiliary(FACT-Hep), FACT-Hep Symptom Index, Trial Outcome Index. Important utilization of HRQOL in HCC patients included description of symptomatology and HRQOL of patients, treatment endpoint in clinical trial, prognostication of survival, benchmarking of palliative care service and health care valuation. In this review, difficulties regarding the use of HRQOL data in research and clinical practice, including choosing a suitable instrument, problems of missing data, data interpretation, analysis and presentation are examined. Potential solutions are also discussed.展开更多
文摘目的:检验世界卫生组织残疾人生存质量量表一般残疾版本(WHOQOL-DIS Scales for PD)中文版的可接受性、信度和效度,以便用于中国残疾人的生存质量的研究。方法:采用多阶段分层随机抽样的方法,从广州市抽取一般残疾人(除智力残疾的其他残疾人)807名。间隔1周后,对自愿进行重复调查的109人进行重测。对量表进行可接受性、信度和效度检验,并以生活满意度量表(SWLS)为校标。结果:量表回收率为99.2%,除了性生活满意度条目缺失率为35.7%,其余条目的缺失率均小于5.0%。量表5个领域的Cronbachα系数为0.77~0.84;间隔1周后重测ICC为0.82~0.91。量表条目与所属领域得分的秩相关系数为0.30~0.84,高于与其他领域的相关性;验证性因子分析显示量表的拟合较好(χ2=2405.57,df=569,RM SEA=0.06,GFI=0.85,CFI=0.87);量表5个领域得分与SWLS得分呈正相关(r=0.15~0.45,均P<0.05)。结论:世界卫生组织残疾人生存质量量表一般残疾版本中文版具有较好的可接受性、信度和效度,可用于中国残疾人生存质量的研究。
文摘Health related quality of life(HRQOL) is increasingly recognized as an important clinical parameter and research endpoint in patients with hepatocellular carcinoma(HCC). HRQOL in HCC patients is multifaceted and affected by medical factor which encompasses HCC and its complications, oncological and palliative treatment for HCC, underlying liver disease, as well as the psychological, social or spiritual reaction to the disease. Many patients presented late with advanced disease and limited survival, plagued with multiple symptoms, rendering QOL a very important aspect in their general well being. Various instruments have been developed and validated to measure and report HRQOL in HCC patients, these included general HRQOL instruments, e.g., Short form(SF)-36, SF-12, Euro Qo L-5D, World Health Organization Quality of Life Assessment 100(WHOQOL-100), World Health Organization Quality of Life Assessment abbreviated version; general cancer HRQOL instruments, e.g., the European Organisation for Research and Treatment of Cancer(EORTC) QLQ-C30, Functional Assessment of Cancer Therapy(FACT)-General, Spitzer Quality of Life Index; and liver-cancer specific HRQOL instruments, e.g., EORTC QLQ-HCC18, FACT-Hepatobiliary(FACT-Hep), FACT-Hep Symptom Index, Trial Outcome Index. Important utilization of HRQOL in HCC patients included description of symptomatology and HRQOL of patients, treatment endpoint in clinical trial, prognostication of survival, benchmarking of palliative care service and health care valuation. In this review, difficulties regarding the use of HRQOL data in research and clinical practice, including choosing a suitable instrument, problems of missing data, data interpretation, analysis and presentation are examined. Potential solutions are also discussed.